A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
This is an open-label, multicenter, Phase I dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics (PK) of GDC-0917 in patients with refractory solid tumors or lymphoma.
Solid Cancers
DRUG: GDC-0917
Changes in vital signs, ECGs, and clinical laboratory results, Throughout study or until early discontinuation|Incidence and nature of dose-limiting toxicities and adverse events of special interest, Throughout study or until early discontinuation|Incidence, nature, and severity of all adverse events and serious adverse events, Throughout study or until early discontinuation
Pharmacokinetic parameters of GDC-0917 (including total exposure, maximum and minimum serum concentration, time to maximum observed plasma concentration, elimination of half-life, accumulation at steady-state), Throughout study or until early discontinuation
This is an open-label, multicenter, Phase I dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics (PK) of GDC-0917 in patients with refractory solid tumors or lymphoma.